To use all functions of this page, please activate cookies in your browser.
My watch list
my.chemeurope.com
my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
21 Current news
rss
Caltech researchers develop nanoscale structures with superior mechanical properties
12-02-2010
, by Dongchan Jang, senior postdoctoral scholar, and Julia R. Greer, assistant professor of materials science and mechanics at Caltech, could eventually lead to the development of innovative, superstrong, yet...
Abgenix Announces Initiation of Phase II Clinical Trial of ABX-EGF in Colorectal Cancer
31-12-2001
clinical oncology program with the start of this third Phase II trial for ABX-EGF,'' stated R. Scott Greer, chairman and chief executive officer of Abgenix. ``Our goal is to provide effective, antibody...
Abgenix Announces Initiation of Phase II Clinical Trial of ABX-EGF in Colorectal Cancer
28-12-2001
clinical oncology program with the start of this third Phase II trial for ABX-EGF," stated R. Scott Greer, chairman and chief executive officer of Abgenix. "Our goal is to provide effective, antibody...
Abgenix Introduces Enhanced Version of XenoMouse Technology
05-12-2001
. ``The generation of these new strains of XenoMouse mice demonstrates our commitment to maintaining technological leadership in the antibody field,'' said R. Scott Greer, chairman and CEO of Abgenix...
Abgenix Acquires Rights To Novel Cancer Target
27-11-2001
specific antibody treatments for cancer,” said R. Scott Greer, chairman and chief executive officer of Abgenix. “We continue to believe that the epidermal growth factor receptor family offers some...
Abgenix Announces CEO Succession Plan
Ray Withy to Become CEO in Mid-2000
20-11-2001
FREMONT, Calif., November 19, 2001 - Abgenix, Inc. (Nasdaq: ABGX) announced today plans for Raymond Withy, Ph.D., to succeed R. Scott Greer as the company?s chief executive officer effective in mid...
Abgenix And Agensys Enter Technology License Collaboration To Discover And Develop Human Therapeutic Antibodies Against Cancer
15-08-2001
the collaboration. "We are excited to enter this alliance with Agensys to generate fully human antibody candidates to their large portfolio of novel, clinically relevant cancer antigens," stated R. Scott Greer...
Abgenix Announces Initiation of Phase II Clinical Trial of ABX-EGF in Non-Small Cell Lung Cancer
01-08-2001
with the second Phase II trial this year for ABX-EGF," stated R. Scott Greer, chairman and chief executive officer of Abgenix. "We are pleased with the progress the joint development team has made in advancing...
Abgenix Reaches Milestone In Antibody Collaboration With Amgen,
11-07-2001
derived from Abgenix technology are in human clinical trials, including two of our own," said R. Scott Greer, chairman and chief executive officer of Abgenix. "We believe our fully human antibody platform...
MDS Proteomics And Abgenix Announce Exclusive Agreement To Develop Proteomic-Based Antibody Therapies,
09-07-2001
, in a large-scale effort to help change the nature of the drug development process," said R. Scott Greer, chairman and chief executive officer of Abgenix. "With MDS Proteomics’ ability to drill down into each...
Netmeeting
